DAITO PHARMACEUTICAL CO.,LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,502 JPY | +0.08% |
|
+0.20% | +31.34% |
| Apr. 12 | Daito Pharmaceutical Co.,Ltd. announces an Equity Buyback for 350,000 shares, representing 2.23% for ¥1,000 million. | CI |
| Apr. 12 | Daito Pharmaceutical Co.,Ltd. authorizes a Buyback Plan. | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- With a P/E ratio at 11.79 for the current year and 10.02 for next year, earnings multiples are highly attractive compared with competitors.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +31.34% | 251M | - | ||
| +19.98% | 43.67B | B- | ||
| +20.67% | 22.51B | B+ | ||
| +14.19% | 14.6B | - | ||
| +14.32% | 13.74B | B+ | ||
| +44.72% | 11.91B | B | ||
| -8.37% | 7.04B | B+ | ||
| -0.05% | 6.79B | - | - | |
| -8.87% | 5.73B | - | - | |
| +10.21% | 5.42B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 4577 Stock
- Ratings Daito Pharmaceutical Co.,Ltd.
